


## GSK2983559 free acid

<b>Cat. No.:</b>	HY-112038		
<b>CAS No.:</b>	1579965-12-0		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>23</sub> N <sub>4</sub> O <sub>7</sub> PS <sub>2</sub>		
<b>Molecular Weight:</b>	538.53		
<b>Target:</b>	RIP kinase		
<b>Pathway:</b>	Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 5 mg/mL (9.28 mM; ultrasonic and warming and heat to 80°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.8569 mL	9.2845 mL	18.5691 mL
5 mM	0.3714 mL	1.8569 mL	3.7138 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

GSK2983559 free acid (compound 3) is a potent, specific and oral bioavailable receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 free acid has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

RIP2<sup>[1]</sup>

### REFERENCES

[1]. Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. *J Med Chem.* 2019 Jul 25;62(14):6482-6494.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA